This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisHoldingsShort InterestTrendsBuy This Stock About Range Cancer Therapeutics ETF (NASDAQ:CNCR) 30 days 90 days 365 days Advanced Chart Get CNCR alerts:Sign Up Key Stats Today's Range$11.63▼$11.8250-Day Range$27.45▼$32.2552-Week Range$7.88▼$16.27Volume1,757 shsAverage Volume4,185 shsMarket Capitalization$7.28 millionAssets Under Management$6.95 millionDividend Yield3.11%Net Expense Ratio0.79%Aggregate RatingN/A ETF OverviewThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More… Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.57%0.57%0.54%0.54%Other Expenses0.00%0.30%0.48%0.42%0.51%Total Expense0.79%0.70%0.72%0.69%0.71%Fee Waiver0.00%-0.45%-0.48%-0.29%-0.54%Net Expense0.79%0.60%0.63%0.62%0.60% Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address CNCR ETF News HeadlinesTango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge FundsNovember 23, 2024 | msn.comBuy Rating Affirmed for TScan Therapeutics Amid Positive Developments in TCR-T Cell Therapy SpaceOctober 12, 2024 | markets.businessinsider.comTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design. June 13, 2025 | Crypto 101 Media (Ad)Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC SubpopulationSeptember 9, 2024 | seekingalpha.comRange Oncology Therapeutics Index ETF (CNCR)August 15, 2024 | finance.yahoo.comTango Therapeutics Shuts Early-Stage Cancer Study Due To Liver ToxicityMay 23, 2024 | msn.comSee More Headlines CNCR ETF - Frequently Asked Questions What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Range Cancer Therapeutics ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Oncology Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings1 Fund Statistics Assets Under Management$6.95 million Average Daily Volume$2.27 thousand Discount/Premium0.12% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest6,900 shs Miscellaneous Outstanding Shares780,814Beta0.95 Creation Unit50,000 Creation Fee$150.00 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report Top 2 CNCR HoldingsUS DOLLARSHolding Weight: 99.94%DEPOSITS WITH BROKER FOR SHORT POSITIONSHolding Weight: 0.06%Full Holdings Details This page (NASDAQ:CNCR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNCR Stock Free CNCR Stock Alerts